Magnus Lagerlund

1.5k total citations · 1 hit paper
11 papers, 849 citations indexed

About

Magnus Lagerlund is a scholar working on Pulmonary and Respiratory Medicine, Hepatology and Radiation. According to data from OpenAlex, Magnus Lagerlund has authored 11 papers receiving a total of 849 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Pulmonary and Respiratory Medicine, 4 papers in Hepatology and 3 papers in Radiation. Recurrent topics in Magnus Lagerlund's work include Prostate Cancer Diagnosis and Treatment (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Prostate Cancer Treatment and Research (4 papers). Magnus Lagerlund is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (6 papers), Hepatocellular Carcinoma Treatment and Prognosis (4 papers) and Prostate Cancer Treatment and Research (4 papers). Magnus Lagerlund collaborates with scholars based in Sweden, Denmark and United Kingdom. Magnus Lagerlund's co-authors include Anders Widmark, Kirsten Björnlinger, Elisabeth Kjellén, Lars Franzén, Claes Ginman, Bengt Johansson, Morten Høyer, Per Nilsson, L. Beckman and Jon Kindblom and has published in prestigious journals such as The Lancet, The Lancet Oncology and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Magnus Lagerlund

9 papers receiving 841 citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial

2019 559 citations Anders Widmark, Adalsteinn Gunnlaugsson et al. The Lancet profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Magnus Lagerlund Sweden	7	621	457	190	189	136	11	849
Biancamaria Saracino Italy	12	832 1.3×	582 1.3×	154 0.8×	192 1.0×	110 0.8×	24	998
Mihai Ghilezan United States	11	564 0.9×	443 1.0×	125 0.7×	151 0.8×	108 0.8×	14	866
Jo-Åsmund Lund Norway	6	849 1.4×	280 0.6×	184 1.0×	259 1.4×	210 1.5×	7	1.0k
A. Zapatero Spain	16	683 1.1×	318 0.7×	134 0.7×	208 1.1×	105 0.8×	89	956
Maria Grazia Petrongari Italy	13	851 1.4×	620 1.4×	183 1.0×	120 0.6×	67 0.5×	27	973
M. Seke Sweden	6	622 1.0×	438 1.0×	184 1.0×	75 0.4×	73 0.5×	6	737
Larry B. Levy United States	12	1.0k 1.7×	441 1.0×	112 0.6×	176 0.9×	90 0.7×	15	1.2k
Debra Freeman United States	9	669 1.1×	520 1.1×	138 0.7×	160 0.8×	75 0.6×	14	866
Hima Bindu Musunuru Canada	15	683 1.1×	356 0.8×	153 0.8×	168 0.9×	85 0.6×	55	823
Ruth Peter United States	8	444 0.7×	338 0.7×	185 1.0×	111 0.6×	105 0.8×	11	629

Countries citing papers authored by Magnus Lagerlund

Since Specialization

Citations

This map shows the geographic impact of Magnus Lagerlund's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Magnus Lagerlund with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Magnus Lagerlund more than expected).

Fields of papers citing papers by Magnus Lagerlund

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Magnus Lagerlund. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Magnus Lagerlund. The network helps show where Magnus Lagerlund may publish in the future.

Co-authorship network of co-authors of Magnus Lagerlund

This figure shows the co-authorship network connecting the top 25 collaborators of Magnus Lagerlund. A scholar is included among the top collaborators of Magnus Lagerlund based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Magnus Lagerlund. Magnus Lagerlund is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

11 of 11 papers shown

Nilsson, P., Adalsteinn Gunnlaugsson, L. Beckman, et al.. (2026). Ultra-hypofractionated versus conventionally fractionated radiotherapy for localised prostate cancer (HYPO-RT-PC): 10-year outcomes of an open-label, randomised, phase 3, non-inferiority trial. The Lancet Oncology. 27(3). 293–301.

Nilsson, Per, Adalsteinn Gunnlaugsson, L. Beckman, et al.. (2025). 4981 Ultra-hypofractionated radiotherapy for localised prostate cancer: 10-year outcomes of the HYPO-RT-PC phase 3 trial (ISRCTN45905321). Radiotherapy and Oncology. 206. S4414–S4415. 1 indexed citations

Engvall, K., Henrik Gréen, Mats Fredrikson, et al.. (2022). Impact of persistent peripheral neuropathy on health-related quality of life among early-stage breast cancer survivors: a population-based cross-sectional study. Breast Cancer Research and Treatment. 195(3). 379–391. 23 indexed citations

Fransson, Per, Per Nilsson, Adalsteinn Gunnlaugsson, et al.. (2021). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial. The Lancet Oncology. 22(2). 235–245. 93 indexed citations

Benstead, Kim, Pedro C. Lara, Lotte Engell-Noerregaard, et al.. (2020). Clinical oncology module for the ESTRO core curriculum. Radiotherapy and Oncology. 156. 19–22. 6 indexed citations

Widmark, Anders, Adalsteinn Gunnlaugsson, L. Beckman, et al.. (2019). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. The Lancet. 394(10196). 385–395. 559 indexed citations breakdown →

Widmark, Anders, Adalsteinn Gunnlaugsson, L. Beckman, et al.. (2018). OC-0599: Ultrahypofractionation for prostate cancer: Outcome from the Scandinavian phase 3 HYPO-RT-PC trial. Radiotherapy and Oncology. 127. S314–S314. 14 indexed citations

Widmark, Anders, Adalsteinn Gunnlaugsson, L. Beckman, et al.. (2016). Extreme Hypofractionation versus Conventionally Fractionated Radiotherapy for Intermediate Risk Prostate Cancer: Early Toxicity Results from the Scandinavian Randomized Phase III Trial “HYPO-RT-PC”. International Journal of Radiation Oncology*Biology*Physics. 96(5). 938–939. 27 indexed citations

Lagerlund, Magnus, et al.. (2008). Clinical outcome following radiotherapy and planned neck dissection in N+ head and neck cancer patients. Acta Oto-Laryngologica. 128(12). 1354–1360. 7 indexed citations

10.

Zackrisson, Björn, Elisabeth Kjellén, Thomas Björk‐Eriksson, et al.. (2007). Preliminary results from a swedish study of conventional versus accelerated fractionated of squamous carcinoma of the head and neck (ARTSCAN). Radiotherapy and Oncology. 82. S1–S2.

11.

Kaasa, Stein, Elisabeth Brenne, Jo-Åsmund Lund, et al.. (2006). Prospective randomised multicenter trial on single fraction radiotherapy (8Gy×1) versus multiple fractions (3Gy×10) in the treatment of painful bone metastases. Radiotherapy and Oncology. 79(3). 278–284. 119 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact